Latest NewLimit News & Updates

See the latest news and media coverage for NewLimit. We track all announcements, press releases, and industry mentions in real time, all in one place.

NewLimit

Biotechnology company developing epigenetic reprogramming medicines for age-related diseases

newlimit.com

Headquarters: South San Francisco, United States
Founded year: 2022
Company type: Private company
Number of employees: 10–70
Industry: Pharmaceuticals

Last updated Today

Latest news about NewLimit

In short: NewLimit raised $435 million in Series C funding to advance clinical trials for its epigenetic reprogramming medicines aimed at aging.

Company announcements

June 9 NewLimit

NewLimit publishes 2026 progress update

AI systems doubled discovery rate, advancing three therapeutic programs and a clinical candidate.

June 2 NewLimit

NewLimit raises $435M for longevity medicine trials

The Series C was led by Founders Fund, and the first medicine reverses cell age in old human liver cells, with trials starting next year.

March 27 NewLimit

NewLimit announces January-February 2026 progress

Discovers new reprogramming payloads restoring hepatocyte functions, advances manufacturing of first candidate, builds AI system doubling discovery rate, and develops kidney endothelial model.

January 6 NewLimit

NewLimit reviews 2025 reprogramming achievements

Built first preclinical candidate restoring youthful hepatocyte functions, developed AI doubling discoveries per dollar, discovered 30+ payloads, launched vascular program.

Media coverage

September 7 Sohu

$636 million sets a new high for the longevity market! Capital frenzy, betting on human trials, financing difficulties for small and medium-sized startups intensify

In Q2 2026, global funding in the longevity sector reached $636 million, nearly doubling quarter-on-quarter, appearing even hotter; but excluding NewLimit's single $435 million deal, the remaining companies received almost the same amount as six months ago—money is accelerating towards the few top companies "able to enter humans," while newcomers and small and medium-sized institutions are being squeezed out of the table...

September 1 MoneyDJ

"US Stock Thematic Weekly Report" Aging Management and Longevity Medicine - SYK, BSX

MoneyDJ News 2026-09-01 15:54:25 Digital Content Center Published NewLimit The signal worth remembering this week is that NewLimit ranked in the top tier of annual private financing with $435 million in BioBucks' 2026 biotech venture capital funding tracking, second only to Isomorphic Labs and Earendil...

June 5 Inc.

A $435 Million Bet on 'Reversing Aging'

Biotech startup NewLimit secures a major funding round after claiming a 'breakthrough discovery' of a prototype medicine that rewinds cellular aging in the liver.

June 3 Yahoo Finance

Coinbase CEO-Backed NewLimit Claims Aging Reversal Breakthrough, Raises $435 Million For Human Trials

Coinbase Global Inc. CEO Brian Armstrong backed biotechnology startup NewLimit, which says it has developed an experimental drug that can partially reverse signs of aging...

Never miss news about NewLimit

Track NewLimit and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

NewLimit competitors & trending companies

Browse news for competitors to NewLimit and other trending companies.